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Efficacy and safety of oral semaglutide with flexible dose 
adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): 
a multicentre, open-label, randomised, phase 3a trial
Thomas R Pieber, Bruce Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Signe O R Wallenstein, John B Buse, for the 
PIONEER 7 investigators
Summary
Background Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist 
developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments 
of oral semaglutide with sitagliptin 100 mg.
Methods In this 52-week, multicentre, randomised, open-label, phase 3a trial, we recruited patients with type 2 diabetes 
from 81 sites in ten countries. Patients were eligible if they were aged 18 years or older (19 years or older in South Korea), 
had type 2 diabetes (diagnosed ≥90 days before screening), HbA1c of 7·5–9·5% (58–80 mmol/mol), and were 
inadequately controlled on stable daily doses of one or two oral glucose-lowering drugs (for 90 days or more before 
screening). Participants were randomly assigned (1:1) by use of an interactive web-response system, stratified b y 
background glucose-lowering medication at screening, to oral semaglutide with flexible dose adjustments to 3, 7, or 
14 mg once daily or sitagliptin 100 mg once daily. To approximate treatment individualisation in clinical practice, oral 
semaglutide dose could be adjusted on the basis of prespecified HbA1c and tolerability criteria. Two efficacy-related 
estimands were prespecified: treatment policy (regardless of treatment discontinuation or use of rescue medication) 
and trial product (on treatment and without use of rescue medication) for participants randomly assigned to treatment. 
The primary endpoint was achievement of HbA1c of less than 7% (53 mmol/mol)  at week 52 and the confirmatory 
secondary efficacy endpoint was change in bodyweight from baseline to week 52. Safety was assessed in all participants 
who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02849080, and 
European Clinical Trials Database, EudraCT number 2015-005593-38, and an open-label extension is ongoing.
Findings Between Sept 20, 2016, and Feb 7, 2017, of 804 patients assessed for eligibility, 504 were eligible and randomly 
assigned to oral semaglutide (n=253) or sitagliptin (n=251). Most participants were male (285 [57%] of 504) with a 
mean age of 57·4 years (SD 9·9). All participants were given at least one dose of their allocated study drug except for 
one participant in the sitagliptin group. From a mean baseline HbA1c of 8·3% (SD 0·6%; 67 mmol/mol [SD 6·4]), a 
greater proportion of participants achieved an HbA1c of less than 7% with oral semaglutide than did with sitagliptin 
(treatment policy estimand: 58% [134 of 230] vs 25% [60 of 238]; and trial product estimand: 63% [123 of 196] vs 
28% [52 of 184]). The odds of achieving an HbA1c of less than 7% was significantly better with oral semaglutide than 
sitagliptin (treatment policy estimand: odds ratio [OR] 4·40, 95% CI 2·89–6·70, p<0·0001; and trial product estimand: 
5·54, 3·54–8·68, p<0·0001). The odds of decreasing mean bodyweight from baseline to week 52 were higher with oral 
semaglutide than with sitagliptin (estimated mean change in bodyweight, treatment policy estimand: –2·6 kg [SE 0·3] 
vs –0·7 kg [SE 0·2], estimated treatment difference [ETD] –1·9 kg, 95% CI –2·6 to –1·2; p<0·0001; and trial product 
estimand: –2·9 kg [SE 0·3] vs –0·8 kg [SE 0·3], ETD –2·2 kg, –2·9 to –1·5; p<0·0001). Adverse events occurred in 
197 (78%) of 253 participants in the oral semaglutide group versus 172 (69%) of 250 in the sitagliptin group, and 
nausea was the most common adverse event with oral semaglutide (53 [21%]). Two deaths occurred in the sitagliptin 
group during the trial.
Interpretation Oral semaglutide, with flexible dose adjustment, based on efficacy and tolerability, provided superior 
glycaemic control and weight loss compared with sitagliptin, and with a safety profile consistent with subcutaneous 
GLP-1 receptor agonists.
Funding Novo Nordisk A/S.
Introduction
Semaglutide, a human glucagon-like peptide-1 (GLP-1) 
analogue, is available as a once weekly subcutaneous 
injection that has been shown to significantly decrease 
glycated haemoglobin (HbA1c) levels and bodyweight in 
people with type 2 diabetes,1–6 and decrease the risk of 
cardiovascular events among those at high cardiovascular 
risk.7
To expand treatment options for patients, semaglutide 
has been developed as an oral formulation. To improve its 
bioavailability after oral administration, semaglutide is 
co-formulated into a tablet with an absorption enhancer, 
sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate, which 
is designed to protect peptides, such as semaglutide, 
from proteolytic degradation and promote absorption 
across the gastric mucosa.8 In the first completed phase 3 
trial to investigate oral semaglutide, PIONEER 1,9,10 
monotherapy with once-daily oral semaglutide at doses of 
3, 7, and 14 mg provided superior and dose-dependent 
decreases in HbA1c compared with placebo, and superior 
decreases in bodyweight at the highest dose, in patients 
with type 2 diabetes whose glycaemia was insufficiently 
controlled on diet and exercise. Oral semaglutide 7 mg 
and 14 mg doses have also shown superior decreases in 
HbA1c and bodyweight compared with sitagliptin in the 
PIONEER 3 trial.11
The phase 3a trial reported herein, PIONEER 7, sought 
to assess the efficacy an d sa fety of  on ce-daily or al 
semaglutide, administered according to an individualised 
and flexible dose-adjustment approach, compared with a 
fixed d ose o f a n e stablished o nce-daily o ral d rug, t he 
dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin. The 
flexible d ose-adjustment a pproach f or o ral s emaglutide 
was designed to mimic the individualised approach used 
in clinical practice, with treatment dose being increased 
or decreased depending on glycaemic efficacy an d 
gastrointestinal tolerability, rather than the fixed-dose 
schedule typically used in clinical trials. To further reflect 
clinical practice and consensus recommendations,12 the 
trial enrolled patients who were already receiving one or 
two oral glucose-lowering drugs.
Methods
Study design
This randomised, open-label, active-controlled, multi-
centre, phase 3a trial was undertaken at 81 sites in 
Argentina (three sites), Austria (three sites), Belgium 
(seven sites), Brazil (two sites), Egypt (four sites), Norway 
(five sites), South Korea (seven sites), Switzerland 
(eight sites), Turkey (eight sites), and the USA (34 sites).
Two different scientific questions associated with 
efficacy were addressed through the definition of two 
estimands: treatment policy and trial product. Both 
estimands were defined on the basis of interactions with 
regulatory agencies.
The treatment policy estimand assesses the treatment 
effect for all randomly assigned participants regardless of 
treatment discontinuation or use of rescue medication. 
The treatment policy estimand was the primary estimand 
for all efficacy endpoints. This estimand reflects the 
intention-to-treat principle as defined in International 
Conference on Harmonisation Guidelines for Good 
Clinical Practice (ICH) E9.13 The estimand reflects the 
effect of initiating treatment with oral semaglutide 
compared with initiating treatment with sitagliptin, both 
potentially followed by discontinuation of study drug, or 
addition of or switch to another glucose-lowering 
medication.
Research in context
Evidence before this study
GLP-1 receptor agonists are an established class of drugs that 
have been shown to have high glucose-lowering efficacy and to 
induce decreases in bodyweight. Available GLP-1 receptor 
agonists include dulaglutide, exenatide, liraglutide, lixisenatide, 
and semaglutide, all of which are only available in subcutaneous 
formulations. Subcutaneous semaglutide has been extensively 
studied in comparison with placebo and various active 
comparators in patients with type 2 diabetes in the phase 3 
SUSTAIN trial programme. The SUSTAIN 2 trial has shown 
improved glycaemic control and decreased bodyweight with 
subcutaneous semaglutide compared with sitagliptin in type 2 
diabetes, when added to metformin or thiazolidinediones, or 
both. We searched PubMed on Jan 17, 2019, with no date or 
language restrictions to identify relevant clinical trials using the 
search term “oral semaglutide”. This search revealed only clinical 
pharmacology studies and a phase 2 dose-finding trial with oral 
semaglutide, which were used to inform the design of the 
current phase 3a PIONEER 7 trial.
Added value of this study
To our knowledge, the PIONEER 7 trial is the first to assess the 
efficacy and safety of oral semaglutide using a flexible 
dose-adjustment approach to approximate clinical practice. 
We found that in patients with type 2 diabetes on one or 
two glucose-lowering drugs, once-daily oral semaglutide with 
flexible dose adjustment (guided by glycaemic efficacy and 
gastrointestinal tolerability) provides superior glycaemic 
control and decreases in bodyweight compared with the DPP-4 
inhibitor, sitagliptin, even though not all patients received or 
needed the highest dose of oral semaglutide to achieve the 
target HbA1c of less than 7% (53 mmol/mol). The safety profile 
of oral semaglutide was consistent with that expected for the 
GLP-1 receptor agonist class.
Implications of all the available evidence
This trial is one of the first phase 3 trials to compare an oral 
GLP-1 receptor agonist with a DPP-4 inhibitor. Additionally, 
the flexible dose-adjustment approach to the administration of 
oral semaglutide might be more relevant to clinical practice. 
Furthermore, our results suggest that oral semaglutide could 
become a promising new oral treatment option for patients 
with type 2 diabetes. Further insights into the efficacy of oral 
semaglutide compared with other glucose-lowering drugs are 
anticipated from additional studies in the comprehensive 
PIONEER clinical trial programme.
The trial product estimand assesses the treatment effect 
for all randomly assigned participants under the 
assumption that all participants remained on treatment 
(oral semaglutide or sitagliptin) for the entire planned 
duration of the trial and did not use rescue medication. 
The trial product estimand was the secondary estimand 
for all efficacy endpoints. This estimand aims to reflect 
the effect of oral semaglutide compared with sitagliptin 
without the confounding effect of rescue medication. The 
statistical analysis that was applied to estimate this 
estimand is similar to that applied in many phase 3a 
diabetes trials. Results from such analyses are currently 
included in many product labels (eg, US prescribing 
information, and European Union summary of product 
characteristics [SmPC]) for glucose-lowering drugs 
(eg, the SmPC for Ozempic).14
Study drug discontinuation and initiation of rescue 
medication are accounted for by the treatment policy 
strategy for the treatment policy estimand and by the 
hypothetical strategy for the trial product estimand as 
defined in draft ICH E9(R1).13 Further details on the 
estimands are in the appendix (pp 2–3).
The trial was undertaken in accordance with ICH Good 
Clinical Practice, the Declaration of Helsinki, and all 
applicable regulatory requirements. The trial protocol 
was approved by the relevant local institutional review 
boards and independent ethics committees. A redacted 
protocol is in the appendix (pp 22–164).
Participants
Eligible patients were aged 18 years or older (or 19 years 
or older in South Korea) with type 2 diabetes (diagnosed 
≥90 days before screening), HbA1c of 7·5–9·5% 
(58–80 mmol/mol), and receiving stable daily doses of 
one or two glucose-lowering drugs (metformin, 
sulphonylureas, sodium glucose co-transporter-2 [SGLT2] 
inhibitors, or thiazolidinediones) for 90 days or more 
before screening. As determined by the investigator, 
patients also needed to be healthy enough to aim for an 
HbA1c treatment target of less than 7·0% (53 mmol/mol). 
Key exclusion criteria included renal impairment 
(estimated glomerular filtration rate [eGFR] of 
<60 mL/min per 1·73 m²); New York Heart Association 
class IV heart failure;15 proliferative retinopathy or 
maculopathy requiring acute treatment; history of 
pancreatitis; family or personal history of multiple 
endocrine neoplasia type 2 or medullary thyroid 
carcinoma; and a history of malignant neoplasms within 
the past 5 years. Full eligibility criteria are in the appendix 
(pp 4–5).
All patients provided written informed consent before 
undertaking any trial-related activities.
Randomisation and masking
Eligible patients were randomly assigned (1:1) to either 
oral semaglutide once daily with flexible dose adjust-
ment or oral sitagliptin 100 mg once daily, in addition 
to existing background glucose-lowering medication. 
Randomisation was stratified according to background 
glucose-lowering medication at screening (with or 
without sulphonylureas) and using an interactive web-
response system. Due to the nature of the intervention 
and so that investigators could escalate the dose of oral 
semaglutide as prespecified, the trial was open label.
Procedures
After a 2-week screening period, participants were 
randomly assigned to receive oral semaglutide once 
daily with flexible dose adjustment or oral sitagliptin 
100 mg once daily for the 52-week treatment period 
(appendix p 9). During the treatment phase, participants 
attended study site visits at weeks 4, 8, 16, 24, 32, 40, 48, 
and 52 regardless of treatment group. After 52 weeks, 
participants could either undergo a 5-week follow-up 
period and complete the trial or, after re-consenting, 
they could continue in a 52-week extension phase. In 
this Article we report on the first 52-week, flexible dose-
adjustment phase of the trial.
All participants who were assigned to oral semaglutide 
were initiated at a 3 mg dose, which they were given until 
week 8. At week 8 and every 8 weeks thereafter, the oral 
semaglutide dose was adjusted on the basis of their 
HbA1c (measured by a point-of-care device) and 
gastrointestinal tolerability. For the purposes of dose 
adjustment, three dose levels were available (3, 7, and 
14 mg). At each study visit, the current dose of oral 
semaglutide was maintained if HbA1c was less than 7·0% 
(53 mmol/mol) and escalated to the next dose level if 
HbA1c was 7·0% (53 mmol/mol) or higher, unless 
participants had reported moderate-to-severe nausea or 
vomiting for 3 or more days in the week before the 
scheduled visit. If participants reported moderate-to-
severe nausea or vomiting, the oral semaglutide dose was 
maintained or decreased to a minimum of 3 mg once 
daily, irrespective of the HbA1c level and at the 
investigator’s discretion. Participants were instructed to 
take the oral semaglutide tablet in the morning, in a 
fasted state, with up to 120 mL of water, at least 30 min 
before any other food, beverage, or other oral medication.
Patients with persistent or unacceptable hyperglycaemia 
were to be offered treatment intensification with rescue 
medication at the investigator’s discretion. From week 32, 
persistent or unacceptable hyperglycaemia was defined 
as HbA1c of 8·5% (69·4 mmol/mol) or higher, assessed at 
a central laboratory (ICON Laboratory Services, Dublin, 
Ireland). Rescue medication was selected in accordance 
with American Diabetes Association (ADA) or European 
Association for the Study of Diabetes guidelines,16 
excluding use of GLP-1 receptor agonists, DPP-4 
inhibitors, and amylin analogues. Participants who 
discontinued study drug prematurely were switched to 
an alternative glucose-lowering drug at the investigator’s 
discretion, including drugs not permitted as rescue 
medication. All participants were followed up throughout 
See Online for appendix
the 52-week trial period irrespective of use of rescue 
medication or premature discontinuation of the assigned 
trial drug, except for those who withdrew consent.
Bodyweight was assessed at baseline  and weeks 8, 16, 
24, 32, 40, 48 and 52, or within 3 days of study drug 
discontinuation. Blood samples were drawn at baseline 
and then every 8 weeks, with HbA1c assessed at these 
timepoints by the central laboratory. Blood samples were 
also assessed for  fasting plasma glucose and fasting lipid 
profile. Details of other efficacy assessments are in the  
appendix (p 6).
We recorded adverse events at every visit, including a 
5-week safety follow-up visit at week 57 or within 3 days 
of study drug discontinuation and again 5 weeks after 
study drug discontinuation. All adverse events were 
coded by use of the Medical Dictionary for Regulatory 
Activities (version 20.1). Adverse events were defined as 
any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal 
product, whether or not considered associated with the 
product. A serious adverse event was defined as any 
event that resulted in death, a life-threatening experience, 
in-patient hospitalisation or extension of existing hospital 
admissions; a full list of eligible events is in the appendix 
(p 6). Details of all safety assessments are in the appendix 
(p 6). An independent external event adjudication 
committee was established for masked validation of 
selected adverse events (death, acute coronary syndrome, 
cerebrovascular event, heart failure requiring admission 
to hospital, acute pancreatitis, malignant neoplasm, 
malignant thyroid neoplasm or C-cell hyperplasia, acute 
kidney injury, and lactic acidosis).
Outcomes
The primary endpoint was achievement of the HbA1c 
target of less than 7·0% (53 mmol/mol) at week 52. The 
confirmatory s econdary e fficacy end point was  cha nge 
from baseline to week 52 in bodyweight. Supportive 
secondary efficacy endpoints were change from baseline 
to week 52 in HbA1c, fasting plasma glucose, BMI, 
bodyweight percentage, waist circumference, lipid 
profile, p atient-reported o utcomes ( Diabetes T reatment 
Satisfaction Questionnaire [DTSQ]; Short Form-36 
[SF-36] version 2 health survey [acute version]); and 
achievement of HbA1c less than or equal to 6·5% 
(48 mmol/mol),17 bodyweight loss of 5% or more or 10% 
or more by week 52, and time to use of rescue medication. 
Composite supportive secondary endpoints assessed 
achievement at week 52 of HbA1c of less than 7% without 
hypoglycaemia (treatment-emergent severe or confirmed 
by blood glucose concentration [<3·1 mmol/L or 
56 mg/dL] symptomatic hypoglycaemia) or weight gain; 
and a HbA1c decrease of 1% (10·9 mmol/mol) or more 
with weight loss of 3% or more. Severe hypoglycaemia 
was defined in accordance with the ADA classification (an 
episode requiring assistance of another person to actively 
administer carbohydrate, glucagon, or take other 
corrective actions).18
Supportive secondary safety endpoints were 
the number of treatment-emergent adverse events, the 
number of symptomatic hypoglycaemic episodes that 
were treatment-emergent severe or confirmed by blood 
glucose concentration, and whether a participant had a 
symptomatic hypoglycaemic episode that was treatment-
emergent severe or confirmed by blood glucose 
concentration up to 52 weeks (yes or no). Other safety 
assessments included changes from baseline to week 52 
in laboratory results, vital signs, electrocardiograms, and 
physical examinations, including eye examinations.
Statistical analysis
We used descriptive statistics to summarise baseline 
demographic information for all participants who were 
randomly assigned to a study drug. We calculated the 
trial sample size to ensure at least 90% power to confirm 
superiority of oral semaglutide versus sitagliptin for the 
primary endpoint (treatment policy estimand), with 
planned enrolment of 500 patients and random 
assignment to treatment to ensure this power was 
achieved. We assumed an absolute difference in 
proportions of 15% and that the proportion of sitagliptin 
responders was distributed around 20–50%.
We used a hierarchical closed-testing strategy to control 
the overall type 1 error for the confirmation of efficacy of 
oral semaglutide for the achievement of HbA1c of less 
than 7% at week 52 and in decrease in bodyweight from 
baseline to week 52 when assessed by use of the 
treatment policy estimand.
 We analysed the primary endpoint using a logistic 
regression model with treatment, region (Africa, Asia, 
Europe, North America, or South America), and 
stratification factor (ie, with or without back-
ground use of sulphonylurea) as fixed effects and 
baseline HbA1c as a covariate for both estimands. The 
treatment effect is presented as an odds ratio (OR) with 
corresponding 95% CI.
We estimated the treatment policy estimand using a 
pattern mixture model with multiple imputation to 
handle missing data at week 52. Data collected at week 52 
from all participants who were randomly assigned to 
treatment, irrespective of premature discontinuation of 
treatment and initiation of rescue medication, were 
included in the statistical analysis. We did imputation 
within groups defined by study drug and treatment 
status at week 52. This imputation was based on an 
analysis of covariance model, whereas we did the 
statistical analysis using a logistic regression model as 
described for the primary endpoint. We combined the 
results using Rubin’s rule.19
We estimated the trial product estimand using a mixed 
model for repeated measurements that used data 
collected before premature discontinuation of study drug 
or initiation of rescue medication from all participants 
who were randomly assigned to study drug. Further 
details on the statistical analyses are in the appendix 
(pp 7–8).
We analysed time from random assignment to 
additional glucose-lowering medication using a Cox 
proportional hazards model with treatment, region, and 
stratification factor as categorical fixed effects and 
baseline HbA1c as a covariate.
We assessed all safety endpoints using data from all 
participants exposed to at least one dose of study drug 
(safety analysis set), and analysed for two observation 
periods: in-trial period (duration in the trial regardless of 
premature discontinuation of study drug) and on-
treatment period (duration on assigned study drug).
We did all analyses using SAS Version 9.4M2. This 
trial is registered with ClinicalTrials.gov, number 
NCT02849080, and the European Clinical Trials Database, 
EudraCT number 2015-005593-38.
Role of the funding source
The funder developed the protocol, provided logistical 
support during the trial, and compiled the data. Data 
were assessed jointly by the authors and the funder. The 
authors interpreted the data and wrote the manuscript, 
with the help of medical writing services funded by the 
sponsor. All authors had full access to the trial data and 
provided final approval to submit the manuscript for 
publication, and the corresponding author had final 
responsibility for the decision to submit.
Results
Between Sept 20, 2016, and Feb 7, 2017, of 804 patients 
assessed for eligibility, 504 were enrolled and randomly 
assigned to treatment with once-daily oral semaglutide 
with flexible dose adjustment (n=253; all at an initial 
dose of 3 mg) or sitagliptin 100 mg (n=251; figure 1). All 
participants were given at least one dose of their 
allocated study drug, except one in the sitagliptin group. 
241 (95%) of 253 participants in the oral semaglutide 
group and 244 (97%) of 251 in the sitagliptin group 
completed the 52-week trial. The treatment schedule 
was completed by 211 (83%) participants in the oral 
semaglutide group and 228 (91%) in the sitagliptin 
group; and 203 (80%) participants in the oral 
semaglutide group and 190 (76%) in the sitagliptin 
group completed the trial without receiving rescue 
medication. Adverse events were the main reason for 
premature discon tinuation of study drug. Demographic 
and baseline characteristics were similar in the two 
treatment groups (table 1). Overall, most participants 
were male (285 [57%] of 504) with a mean age of 
57·4 years (SD 9·9), mean duration of diabetes of 
8·8 years (SD 6·2), mean HbA1c of 8·3% (SD 0·6%; 
67 mmol/mol [SD 6·4]), mean bodyweight of 88·6 kg 
(SD 19·8), and mean BMI of 31·5 kg/m² (SD 6·3). 
Overall, 203 (40%) of 504 partici pants were receiving 
one concomitant glucose-lowering drug at baseline 
(primarily metformin), 299 (59%) were receiving 
two concomitant glucose-lowering drugs (mostly 
metformin plus a sulphonylurea), and two (<1%) were 
receiving three concomitant glucose-lowering drugs 
(protocol violation, participants included in full analysis 
set; table 1).
In the oral semaglutide group, 185 (73%) of 253 patients 
were escalated to the 7 mg dose at week 8 (appendix p 10). 
Of 212 participants on treatment at week 52, 19 (9%) 
were receiving 3 mg, 64 (30%) were receiving 7 mg, and 
126 (59%) were receiving 14 mg of oral semaglutide (dose 
information was missing for the remaining three [1%] 
patients at week 52, but the last known dose was 7 mg for 
one participant and 14 mg for two participants). Twice as 
many participants were given additional glucose-
lowering drugs and more than four-times as many 
partipants were given rescue medication in the sitagliptin 
group compared with the oral semaglutide group 
(appendix p 14).
For the treatment policy estimand,  the HbA1c target 
of less than 7% (53 mmol/mol) at week 52 was achieved 
by 134 (58%) of 230 participants in the oral semaglutide 
group versus 60 (25%) of 238 participants with 
sitagliptin (figure 2). The odds of achieving HbA1c of 
less than 7% were higher with oral semaglutide than 
with sitagliptin (OR 4·40, 95% CI 2·89–6·70; p<0·0001). 
For the trial product estimand, HbA1c of less than 7% at 
253 randomly assigned to oral semaglutide
253 received treatment
211 completed treatment‡
 203 completed without rescue medication
241 completed trial
804 patients assessed for eligibility
504 enrolled
300 excluded
281 did not meet eligibility criteria
19 other reasons
42 discontinued treatment
22 due to adverse events
3 withdrew 
5 due to violation of inclusion or
exclusion criteria
 12 other reasons
 12 withdrew from the trial
251 randomly assigned to sitagliptin
250 received treatment
1 did not receive treatment*
228 completed treatment
 190 completed without rescue medication
244 completed trial
23 discontinued treatment
10 due to adverse events
1 withdrew 
1 due to pregnancy
2 due to violation of inclusion or
exclusion criteria†
 9 other reasons
 7 withdrew from the trial
Figure 1: Trial profile
*This participant was included in the analysis for the treatment policy estimand, but excluded from the safety 
analysis set. †Includes the one participant who was not exposed to study drug. ‡Excludes one participant with 
missing visit 10 (week 52) data and who reported discontinuation of study drug after the end of trial date. 
week 52 was achieved by 123 (63%) of 196 participants 
in the oral semaglutide group and 52 (28%) of 
184 participants in the sitagliptin group (figure 2). The 
odds of achieving HbA1c of less than 7% at week 52 were 
significantly better with oral semaglutide than with 
sitagliptin (OR 5·54, 95% CI 3·54–8·68; p<0·0001).
Oral semaglutide was superior to sitagliptin in 
decreasing bodyweight from baseline to week 52 
(treatment policy estimand: estimated treatment 
difference [ETD] –1·9 kg, 95% CI –2·6 to –1·2; p<0·0001; 
and trial product estimand: ETD –2·2 kg, –2·9 to –1·5; 
p<0·0001; figure 3). 
Estimated mean HbA1c levels at week 52 were 7·0% 
(SE 0·1; 53 mmol/mol [SE 1]) with oral semaglutide and 






Age, years 56·9 (9·7) 57·9 (10·1)
Sex
Female 108 (43%) 111 (44%)
Male 145 (57%) 140 (56%)
Race
White 195 (77%) 186 (74%)
Black or African American 22 (9%) 25 (10%)
Asian 34 (13%) 38 (15%)
Other 2 (1%) 2 (1%)
Ethnicity
Hispanic or Latino 48 (19%) 57 (23%)
Not Hispanic or Latino 205 (81%) 194 (77%)
Clinical
HbA1c, % 8·3 (0·6) 8·3 (0·6)
HbA1c, mmol/mol 67·0 (6·3) 67·2 (6·5)
Duration of diabetes, years 8·6 (6·3) 9·0 (6·2)
Fasting plasma glucose, mmol/L 9·8 (2·4) 9·8 (2·6)
Bodyweight, kg 88·9 (19·6) 88·4 (20·1)
BMI, kg/m² 31·5 (6·5) 31·5 (6·1)
eGFR, mL/min per 1·73 m²* 97·0 (14·4) 95·3 (15·6)
Background medication at baseline
Participants receiving one type of 
concomitant glucose-lowering drug
106 (42%) 97 (39%)
Metformin 102 (40%) 87 (35%)
Sulphonylurea 3 (1%) 6 (2%)
SGLT2 inhibitor 1 (<1%) 3 (1%)
Thiazolidinedione 0 1 (<1%)
Participants receiving two types of 
concomitant glucose-lowering 
drugs
146 (58%) 153 (61%)
Metformin plus sulphonylurea 119 (47%) 116 (46%)
Metformin plus SGLT2 inhibitor 16 (6%) 31 (12%)
Metformin plus thiazolidinedione 9 (4%) 3 (1%)
Metformin plus other 1 (<1%) 0
Sulphonylurea plus other 1 (<1%) 3 (1%)
Participants receiving three types of concomitant 
glucose-lowering drugs†
Metformin plus SGLT2 inhibitor 
plus sulphonylurea
1 (<1%) 1 (<1%)
Data are mean (SD) or n (%). eGFR=estimated glomerular filtration rate. 
HbA1c=glycated haemoglobin. SGLT2=sodium-glucose co-transporter 2. 
*Estimated using the Chronic Kidney Disease-Epidemiology Collaboration 
formula. †Participants receiving three drugs at baseline were protocol violations 
(of these patients, one in the oral semaglutide group received study drug for 
10 days before discontinuation, and one in the sitagliptin group received study 
drug for 30 days before discontinuation; both participants continued in the trial 
until week 52).
Table 1: Baseline characteristics of all participants randomly assigned to 


























A Mean baseline HbA1c: 8·3%




























B Mean baseline HbA1c: 8·3%
(SD 0·6; 67·1 mmol/mol [SD 6·4])
28%
63%
Figure 2: Proportion of participants achieving HbA1c target of less than 
7% (53 mmol/mol) at week 52 for the treatment policy estimand (A) and the 
trial product estimand (B)
Proportions of participants achieving HbA1c of less than 7% are based on 
observed data, with number of participants analysed being the number with 
non-missing information—ie, who attended the week 52 visit and contributed 
to the proportions. HbA1c=glycated haemoglobin.
the treatment policy estimand and 6·9% (SE 0·1; 
52 mmol/mol [SE 1]) versus 7·6% (SE 0·1; 60 mmol/mol 
[SE 1]) for the trial product estimand. Oral semaglutide 
resulted in significantly greater decreases in HbA1c than 
sitagliptin did at week 52 (treatment policy estimand: 
ETD –0·5%, 95% CI –0·7 to –0·4 [–6 mmol/mol, 95% CI 
–7 to –4], p<0·0001; trial product estimand: ETD –0·7%,
–0·9 to –0·5 [–8 mmol/mol, –9 to –6], p<0·0001;
figure 4).
More participants achieved a bodyweight loss of 5% 
or more and 10% or more with oral semaglutide than 
did with sitagliptin, and the odds of achieving these 
weight losses were significantly better with oral 
semaglutide than with sitagliptin (for ≥5% bodyweight 
loss, p<0·0001 for both estimands; for ≥10% bodyweight 
loss, p=0·0156 for treatment policy estimand and 
p=0·0065 for trial product estimand; appendix 
pp 12–13). Additionally, fasting plasma glucose was 
decreased from baseline significantly more with oral 
semaglutide than with sitagliptin at week 52 (treatment 
policy estimand, p=0·0002; trial product estimand, 
p<0·0001; appendix pp 12–13). Further data for 
supportive secondary endpoints, including change 
from baseline to week 52 in BMI, bodyweight 














































































A Mean baseline bodyweight: 88·6 kg (SD 19·8)





















Time since randomisation (weeks)
Oral semaglutide Sitagliptin
253 251









ETD –1·9, 95% CI –2·6 to –1·2; p<0·0001
































































Figure 3: Changes in bodyweight with oral semaglutide compared with sitagliptin by use of the treatment policy estimand (A and B) and trial product 
estimand (C and D)
(A and C) Observed change in mean bodyweight over time from baseline by week, and (B and D) estimated mean change in bodyweight from baseline to week 52. 
For panels A and C, error bars are the SEM. For panels B and D, n are number of participants contributing to the proportions. ETD=estimated treatment difference.
percentage, waist circumference, and lipid profile, and 
proportion of patients achieving HbA1c of 6·5% 
(48 mmol/mol) or less, are reported in the 
appendix (pp 12–13). The results of these supportive 
secondary endpoints are consistent with those of the 
primary and confirmatory secondary endpoints. 
For patient-reported outcomes, change from baseline to 
week 52 in DTSQ scores, satisfaction with treatment, 
convenience and flexibility o f t reatment, and total t reat-
ment satisfaction appeared similar for oral semaglutide 
and sitagliptin with no significant d ifferences for ei ther 
estimand (appendix p 11). The ETD significantly favoured 
oral semaglutide over sitagliptin with regard to decreased 
feelings of unacceptably high blood sugars for 
both estimands. No differences were seen in the 
SF-36 version 2 health survey responses between groups 
(appendix p 11).
The odds for achieving the composite supportive 
secondary endpoints (HbA1c less than 7% [53 mmol/mol], 
without hypoglycaemic episodes and without increase in 
bodyweight; and decrease of HbA1c of 1% or more with 
weight loss of 3% or more) were significantly better with 
oral semaglutide than with sitagliptin (p<0·0001 for both 




































ETD –0·5, 95% CI –0·7 to –0·4; p<0·0001













































































A Mean baseline HbA1C: 8·3% (SD 0·6; 67·1 mmol/mol [SD 6·4])
Oral semaglutide
Sitagliptin
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Figure 4: Changes in HbA1c with oral semaglutide versus sitagliptin by use of the treatment policy estimand (A and B) and trial product estimand (C and D)
(A and C) Observed change in mean HbA1c over time from baseline by week, and (B and D) estimated mean change in HbA1c from baseline to week 52. For panels 
A and C, error bars are SEMs. For panels B and D, n are number of participants contributing to the proportions. Changes from baseline (67·1 mmol/mol) in HbA1c in 
mmol/mol for the treatment policy estimand were –14 mmol/mol with oral semaglutide and –8 mmol/mol for sitagliptin, and for the trial product estimand were 
–15 mmol/mol with oral semaglutide and –8 mmol/mol for sitagliptin. ETD=estimated treatment difference. HbA1c=glycated haemoglobin.
Fewer participants in the oral semaglutide group 
required rescue medication than did in the sitagliptin 
group (appendix p 14). Additional glucose-lowering 
medications used during the trial for the full analysis set 
are reported in the appendix (p 14). Time to first dose of 
rescue medication was significantly longer with oral 
semaglutide than with sitagliptin (hazard ratio [HR] 0·18, 
95% CI 0·09–0·39; p<0·0001), as was the time to 
additional glucose-lowering drug or rescue medication 
(HR 0·58, 0·37–0·91; p=0·0175). 
The number of adverse events and proportion of 
participants who had adverse events were higher in the 
oral semaglutide group (197 [78%] of 253) than in the 
sitagliptin group (172 [69%] of 250) during the on-
treatment period (table 2). The most frequently reported 
adverse events were gastrointestinal events (appendix 
p 15), most commonly nausea and diarrhoea that were 
predominantly mild-to-moderate in severity and of 
short duration, and occurred more frequently in the 
oral semaglutide group than in the sitagliptin group 
(table 2). Most adverse events were mild-to-moderate in 
severity in both treatment groups. The incidence of 
serious adverse events was similar in the oral 
semaglutide and sitagliptin groups during the on-
treatment period (table 2). More participants in the oral 
semaglutide group than in the sitagliptin group 
prematurely discontinued their allocated study drug 
because of adverse events, primarily gastrointestinal 
events. Most discontinuations in the oral semaglutide 
group occurred within the first 8 weeks of the trial (data 
not shown). No deaths occurred in the oral semaglutide 
group, and two deaths occurred during the trial in the 
sitagliptin group, both of which were cardiovascular 
deaths in participants with a history of cardiovascular 
disease and were judged by the investigator to be 
unlikely related to study drug (one during the on-
treatment phase, the other during the in-trial phase; 
table 2; appendix p 16).
No severe hypoglycaemic episodes occurred during 
the trial (appendix p 17). The proportion of participants 
who had symptomatic hypoglycaemic episodes that 
were confirmed by blood glucose concentration was low 
and similar between treatment groups, and most 
episodes occurred in participants who were receiving 
background therapy with a sulphonylurea (appendix 
p 17).
 Adverse events associated with diabetic retinopathy 
were reported in the same proportion of participants in 
both groups (oral semaglutide: six [2%] of 253; sitagliptin: 
six [2%] of 250; in-trial period; appendix p 18). Event 
adjudication committee-confirmed malignant neoplasms 
were reported in eight (3%) of 253 participants in the oral 
semaglutide group and in two (1%) of 250 in the 
sitagliptin group, and with no clustering of malignancies 
to specific organ systems (appendix p 15). No cases of 
pancreatitis were reported. Mean lipase and amylase 
concentrations were increased in both treatment groups 
compared with baseline, with no difference between 
groups (data not shown). No other clinically relevant 
changes in blood pressure, pulse rate, or eGFR were 
reported (appendix p 19).
Discussion
In this trial, oral semaglutide with flexible dose 
adjustment (3, 7, or 14 mg) was found to be superior to 
sitagliptin 100 mg for achievement of an HbA1c target of 
less than 7% (53 mmol/mol) after 52 weeks when added 
to existing therapy with one or two glucose-lowering 
drugs in patients with type 2 diabetes. The proportion of 
participants who achieved this target with oral 
semaglutide was over twice that in the sitagliptin group 
despite the flexible dose-adjustment approach and 
despite twice as many participants receiving additional 
glucose-lowering drugs in the sitagliptin group compared 
with the oral semaglutide group. Additionally, oral 
semaglutide with flexible dose adjustment was superior 
to sitagliptin in decreasing bodyweight. In the present 
trial, patient-reported total treatment satisfaction, 
treatment convenience, and flexibility with once-daily 
oral semaglutide were similar to those reported for once-
daily sitagliptin, which could suggest that the dosing 
conditions for oral semaglutide had little effect on 
treatment convenience or satisfaction. These data 
Oral semaglutide group (n=253) Sitagliptin group (n=250)
Participants with 




at least one event
Number of 
events
All adverse events 197 (78%) 768 172 (69%) 519
Serious adverse events 24 (9%) 28 24 (10%) 30
Fatal events 0 ·· 1 (<1%)* 1*
Adverse event severity
Severe 16 (6%) 31 18 (7%) 20
Moderate 104 (41%) 196 75 (30%) 143
Mild 167 (66%) 541 144 (58%) 356
Premature discontinuation of study 
drug due to adverse events
22 (9%) 35 8 (3%) 13
Most frequent cause of premature study drug discontinuation by system organ class†
Gastrointestinal disorders 14 (6%) 19 2 (1%) 2
Most frequent adverse events ‡
Nausea 53 (21%) 83 6 (2%) 8
Nasopharyngitis 26 (10%) 30 13 (5%) 15
Headache 25 (10%) 33 15 (6%) 15
Diarrhoea 22 (9%) 25 8 (3%) 11
Abdominal pain upper 16 (6%) 17 3 (1%) 3
Vomiting 14 (6%) 21 2 (1%) 2
Dyspepsia 13 (5%) 13 2 (1%) 4
Upper respiratory tract infection 9 (4%) 9 15 (6%) 16
*An additional in-trial fatal adverse event occurred in the sitagliptin group, which occurred 78 days after premature 
discontinuation of the study drug; both fatal events were cardiovascular deaths in participants with a history of 
cardiovascular disease. †Occurring in ≥3% of participants in either group. ‡Occurring in ≥5% of participants in either 
group, defined by use of Medical Dictionary for Regulatory Activities (version 20·1) preferred term.
Table 2: On-treatment adverse events (safety analysis set)
Several considerations and potential limitations need 
to be addressed when interpreting these results. A 
strength of this trial is that it implements the estimand 
concept, which is now recommended by regulatory 
bodies.13 The two estimands used here are comple-
mentary and provide insight into treatment effects that 
are relevant for regulators and payers focusing on 
comparing treatment policies (the treatment policy 
estimand: data from all patients regardless of study drug 
discontinuation or use of rescue medication), and 
physicians seeking to understand the anticipated treat-
ment effect attributable to the study drug (the trial 
product estimand: data from all participants that were 
randomly assigned to a study drug and not initiating 
rescue medication). In the present trial, the conclusions 
from the two estimands were broadly consistent, 
reflecting the high proportion of participants in both 
groups who completed treatment without use of rescue 
medication.
Another strength of the current trial is that it provides 
information that is clinically relevant for physicians who 
are treating patients with diabetes. This relevance was 
achieved by the use of a clinically important primary 
endpoint (achievement of the HbA1c target of less than 
7% [53 mmol/mol]) and also by implementing a flexible 
dose-adjustment approach that more closely replicates 
the individualised approach of adjusting dose according 
to efficacy and tolerability that might be used for oral 
semaglutide in future clinical practice. Additionally, all 
participants were required to be taking stable doses of 
one or two glucose-lowering drugs at enrolment, with the 
study drugs added to this background therapy. This 
patient population reflects current treatment consensus, 
which recommends GLP-1 receptor agonists as add-on 
therapy after initial glucose-lowering therapy with 
metformin,12 and supports the relevance of the trial 
results for clinical practice. The trial was open-label and 
therefore knowledge of the administered treatment could 
have influenced participant and investigator behaviour 
during the trial, including adverse event reporting. 
A further limitation of this trial is that the criteria for 
dose adjustment specified in the protocol restricted 
physicians to maintaining the current dose once 
participants reached the glycaemic targets. Consequently, 
the maximum potential benefits of treat ment with oral 
semaglutide might not have been achieved in all 
participants.
In conclusion, this study shows the superiority of 
flexible dose adjustment with oral semaglutide compared 
with a fixed dose of the DPP-4 inhibitor sitagliptin in 
terms of both achievement of target HbA1c and decrease 
in bodyweight. These benefits were observed despite the 
lower use of additional glucose-lowering drugs with oral 
semaglutide than with sitagliptin. Oral semaglutide had 
a safety profile consistent with the GLP-1 receptor agonist 
class.
suggest that treatment with oral semaglutide can be 
individualised and, even though at week 52 more than  a 
third of participants were not receiving the maximum 
dose, it can help more patients achieve HbA1c targets 
than sitagliptin can.
The most frequently reported adverse events were 
gastrointestinal in nature, most commonly nausea and 
diarrhoea, which were typically mild to moderate. The 
overall safety profile of oral semaglutide in our trial was 
similar to that previously reported in a phase 2 trial,20 in 
the phase 3 PIONEER 19,10 and PIONEER 311 trials, 
and with that of subcutaneous semaglutide1–3 and other 
GLP-1 receptor agonists.21,22 In the present study, 
hypoglycaemic episodes occurred in a similar proportion 
of participants  between the oral semaglutide group 
and the sitagliptin group, few with blood glucose 
concentrations below 3·1 mmol/L, and almost 
all occurred in participants receiving background 
sulphonylurea treatment. Notably, approximately half of 
participants enrolled were treated with sulphonylurea, 
alone or in combination with another glucose-lowering 
drug. Although the increased risk of hypoglycaemia with 
GLP-1 receptor agonists is low,23 caution and close 
monitoring of patients is advisable when adding a GLP-1 
receptor agonist to an existing treatment associated with 
hypoglycaemia.
Individualised dose adjustments of semaglutide 
could be expected to help mitigate adverse events and 
minimise treatment discontinuation. However, flexible 
dose adjustment did not decrease the prevalence of 
study drug discontinuations due to adverse events 
compared with that observed in other oral semaglutide 
studies.10,11,20 Indeed, in PIONEER 3, study drug 
discontinuation due to adverse events over 78 weeks 
occurred in 6% (26 of 466) of participants on 3 mg 
once-daily oral semaglutide, 6% (27 of 464) on 7 mg, 
and 12% (54 of 465) on 14 mg.10,11 In our trial, 9% of 
participants in the oral semaglutide group prematurely 
discontinued study drug due to adverse events. 
However, this was an open-label study of shorter 
duration (52 weeks) than PIONEER 3 (78 weeks), and 
participants were asked about adverse events at all 
visits, which could have influenced t heir d ecisions t o 
discontinue treatment and might have influenced 
clinician or investigator focus on gastrointestinal toler-
ability when discussing with participants. Most adverse 
events that led to study drug discontinuation in the 
present trial occurred within the first 8  w eeks o f t he 
trial, before any dose adjustment, and few additional 
participants discontinued therapy after the main 
dose escalation timepoints (immediately after 
weeks 8 and 16). This observation suggests that 
clinicians seeking increased effect in glycaemic control 
or weight loss might consider further escalation of oral 
semaglutide if tolerability is not a factor after the first 
few weeks of treatment.
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